Mgr. Michal Šmída, Dr. rer. nat.
Research Group Leader Junior, Michal Šmída Research Group
office: bldg. E35/186
Kamenice 753/5
625 00 Brno
phone: | +420 532 23 5494, +420 736 722 290 |
---|---|
e‑mail: |
social and academic networks: |
---|
Total number of publications: 79
2025
-
Thieno[3,2-b]pyridine: Attractive scaffold for highly selective inhibitors of underexplored protein kinases with variable binding mode
Angewandte Chemie International Edition, year: 2025, volume: 64, edition: 1, DOI
2024
-
A novel thrombocytopenia-4-causing CYCS gene variant decreases caspase activity: Three-generation study
British journal of haematology, year: 2024, volume: 205, edition: 6, DOI
-
ANALYSIS OF ALTERNATIVE THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA PATIENTS RESISTANT TO VENETOCLAX BASED ON DRUG SCREENING AND EXPRESSION PROFILING
Year: 2024, type: Conference abstract
-
CD20 expression regulates CD37 levels in B-cell lymphoma - implications for immunotherapies
Oncoimmunology, year: 2024, volume: 13, edition: 1, DOI
-
EXPLORING VENETOCLAX RESISTANCE MECHANISMS IN AML CELLS THROUGH GENOME-WIDE CRISPR SCREENS AND DRUG PROFILING
Year: 2024, type: Conference abstract
-
Novel casein kinase 1 alpha inhibitors for the treatment of resistant AML and solid tumors
Year: 2024, type: Conference abstract
2023
-
CRISPR/Cas9 technology as a useful tool in the study of chornic lymphocytic leukemia.
Year: 2023, type: Conference abstract
-
CRISPR/Cas9 technology as a useful tool in the study of chronic lymphocytic leukemia.
Year: 2023, type: Conference abstract
-
Efficacy of CD19-directed CAR-T cells against CLL and the possibilities for its further improvements.
Year: 2023, type: Requested lectures
-
Exploring the mechanisms of Venetoclax resistence via drug screening and genome-wide CRISPR screening.
Year: 2023, type: Conference abstract